These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16149650)

  • 1. [Osteoprotegerin (OPG)].
    Takahashi N; Kimura H; Yoshida H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():818-20. PubMed ID: 16149650
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma.
    Depil S; Mathiot C; Leleu X; Moreau AS; Faucompré JL; Hennache B; Bauters F; Bataille R; Facon T
    Br J Haematol; 2005 Jun; 129(5):706-7. PubMed ID: 15916694
    [No Abstract]   [Full Text] [Related]  

  • 3. [Osteoclast-activating factors (OAF)].
    Sato K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():228-31. PubMed ID: 15658306
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
    Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
    Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002.
    Dovio A; Sartori ML; Angeli A
    Clin Cancer Res; 2003 Jun; 9(6):2384-5; author reply 2386. PubMed ID: 12796409
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin levels in healthy controls and cancer patients.
    Lipton A; Ali SM; Leitzel K; Chinchilli V; Witters L; Engle L; Holloway D; Bekker P; Dunstan CR
    Clin Cancer Res; 2002 Jul; 8(7):2306-10. PubMed ID: 12114435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Soluble tumor necrosis factor receptor I, II].
    Takemura M; Saito K; Seishima M
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():158-60. PubMed ID: 16149477
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG].
    Sasaki N; Kusano E
    Clin Calcium; 2006 Jun; 16(6):956-62. PubMed ID: 16751691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy.
    Yano K; Shibata O; Mizuno A; Kobayashi F; Higashio K; Morinaga T; Tsuda E
    Biochem Biophys Res Commun; 2001 Oct; 288(1):217-24. PubMed ID: 11594776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity.
    Kim SM; Lee J; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):594-8. PubMed ID: 16268814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis.
    Schoppet M; Sattler AM; Schaefer JR; Hofbauer LC
    Atherosclerosis; 2006 Feb; 184(2):446-7. PubMed ID: 16325821
    [No Abstract]   [Full Text] [Related]  

  • 18. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
    Dovio A; Data V; Angeli A
    Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
    Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.